The 4S study and its pharmacoeconomic implications

Pharmacoeconomics. 1996 Feb;9(2):101-5. doi: 10.2165/00019053-199609020-00001.
No abstract available

MeSH terms

  • Anticholesteremic Agents / economics*
  • Anticholesteremic Agents / therapeutic use
  • Coronary Disease / economics*
  • Coronary Disease / prevention & control
  • Cost-Benefit Analysis
  • Humans
  • Lovastatin / analogs & derivatives*
  • Lovastatin / economics
  • Lovastatin / therapeutic use
  • Scandinavian and Nordic Countries
  • Simvastatin

Substances

  • Anticholesteremic Agents
  • Lovastatin
  • Simvastatin